Albumin/globulin ratio
Pro Research Analysisby 
Searched over 200M research papers for "albumin/globulin ratio"
The Prognostic Significance of the Albumin/Globulin Ratio in Various Cancers
Introduction to Albumin/Globulin Ratio (AGR)
The albumin/globulin ratio (AGR) is a significant biomarker derived from serum protein levels, reflecting both nutritional and inflammatory status. This ratio has been extensively studied for its prognostic value in various cancers, providing insights into patient outcomes and aiding in clinical decision-making.
AGR as a Prognostic Marker in Human Cancers
General Cancer Prognosis
A comprehensive meta-analysis involving 28 studies and 15,356 cancer patients demonstrated that a low pretreatment AGR is significantly associated with poor overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Specifically, low AGR was linked to a higher hazard ratio (HR) for poor OS (HR=2.08 univariate, HR=1.75 multivariate), DFS (HR=1.96 univariate, HR=1.64 multivariate), and PFS (HR=1.89 univariate, HR=1.66 multivariate). Additionally, low AGR was correlated with increased 5-year mortality (RR=2.12) .
Renal Cell Carcinoma (RCC)
In patients with renal cell carcinoma, a meta-analysis of nine studies involving 5,671 cases found that a low AGR significantly predicted worse OS (HR=1.82) and PFS (HR=2.44). Furthermore, low AGR was associated with adverse clinicopathological features such as higher tumor stage, nodal involvement, and tumor necrosis .
Prostate Cancer
For prostate cancer (PC), a meta-analysis revealed that AGR has a significant prognostic value in metastatic cases. Low AGR was independently predictive of worse progression-free survival (PFS) and cancer-specific survival (CSS) in metastatic PC (OR for PFS=0.642, OR for CSS=0.412). However, in non-metastatic PC, AGR did not show significant predictive value for staging, grading, or biochemical progression .
Digestive System Cancers
A meta-analysis focusing on digestive system cancers (DSCs) indicated that a low AGR is significantly associated with poor OS (HR=1.94) and DFS (HR=1.49). This suggests that AGR can be a useful prognostic marker in DSCs, aiding in the prediction of patient outcomes .
Colorectal Cancer
In colorectal cancer (CRC), a meta-analysis of 11 studies with 8,397 patients found that a low AGR was significantly associated with poor OS (HR=2.58) and DFS/PFS (HR=2.11). However, AGR was not a significant prognostic factor for CSS in CRC .
Gastric Cancer
For gastric cancer (GC) patients undergoing curative surgery, low AGR was identified as an independent predictor of early recurrence and poor prognosis. This was particularly evident in patients with lymph node metastasis and serosal invasion, where low AGR was associated with significantly worse disease-free survival .
Cervical Cancer
In cervical cancer patients treated surgically, a low preoperative AGR was significantly associated with poor prognosis. Multivariate analysis confirmed that low AGR was an independent prognostic factor for overall survival (HR=2.59) .
Conclusion
The albumin/globulin ratio (AGR) is a valuable prognostic marker across various types of cancers. Low AGR consistently correlates with poorer survival outcomes and adverse clinicopathological features, making it a critical factor in cancer prognosis and management. Its utility spans multiple cancer types, including renal cell carcinoma, prostate cancer, digestive system cancers, colorectal cancer, gastric cancer, and cervical cancer. As such, AGR should be considered in clinical evaluations to better predict patient outcomes and tailor treatment strategies accordingly.
Sources and full results
Most relevant research papers on this topic